CA2870907A1 - Composition for treating metabolic disorders - Google Patents

Composition for treating metabolic disorders Download PDF

Info

Publication number
CA2870907A1
CA2870907A1 CA 2870907 CA2870907A CA2870907A1 CA 2870907 A1 CA2870907 A1 CA 2870907A1 CA 2870907 CA2870907 CA 2870907 CA 2870907 A CA2870907 A CA 2870907A CA 2870907 A1 CA2870907 A1 CA 2870907A1
Authority
CA
Canada
Prior art keywords
extract
composition
plant
elliptica
terminalia elliptica
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2870907
Other languages
English (en)
French (fr)
Inventor
Arvind Saklani
Nilesh MALPURE
Parikshit GAIKWAD
Satish Namdeo Sawant
Tukaram Kisanrao Mane
Somesh Sharma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Piramal Enterprises Ltd
Original Assignee
Piramal Enterprises Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramal Enterprises Ltd filed Critical Piramal Enterprises Ltd
Publication of CA2870907A1 publication Critical patent/CA2870907A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA 2870907 2012-04-23 2013-04-22 Composition for treating metabolic disorders Abandoned CA2870907A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261636792P 2012-04-23 2012-04-23
US61/636,792 2012-04-23
PCT/IB2013/053155 WO2013160811A1 (en) 2012-04-23 2013-04-22 Composition for treating metabolic disorders

Publications (1)

Publication Number Publication Date
CA2870907A1 true CA2870907A1 (en) 2013-10-31

Family

ID=49482298

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2870907 Abandoned CA2870907A1 (en) 2012-04-23 2013-04-22 Composition for treating metabolic disorders

Country Status (16)

Country Link
US (1) US20150290265A1 (enEXAMPLES)
EP (1) EP2841080A4 (enEXAMPLES)
JP (1) JP2015514797A (enEXAMPLES)
KR (1) KR20150003862A (enEXAMPLES)
CN (1) CN104244962A (enEXAMPLES)
AU (1) AU2013254329A1 (enEXAMPLES)
BR (1) BR112014026326A2 (enEXAMPLES)
CA (1) CA2870907A1 (enEXAMPLES)
IL (1) IL235317A0 (enEXAMPLES)
IN (1) IN2014MN02269A (enEXAMPLES)
MX (1) MX2014012742A (enEXAMPLES)
NZ (1) NZ701133A (enEXAMPLES)
RU (1) RU2014145931A (enEXAMPLES)
SA (1) SA113340494B1 (enEXAMPLES)
TW (1) TW201343174A (enEXAMPLES)
WO (1) WO2013160811A1 (enEXAMPLES)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016099944A1 (en) * 2014-12-19 2016-06-23 Halo Life Science, Llc Use of ellagic acid dihydrate in pharmaceutical formulations to regulate blood glucose levels
EP3529245A4 (en) 2016-10-24 2020-12-23 Yumanity Therapeutics, Inc. COMPOUNDS AND USES OF THE LATEST
EP3566055B1 (en) 2017-01-06 2025-03-12 Janssen Pharmaceutica NV Scd inhibitor for the treatment of neurological disorders
US11873298B2 (en) 2017-10-24 2024-01-16 Janssen Pharmaceutica Nv Compounds and uses thereof
AU2019207737B2 (en) 2018-01-10 2023-07-13 Brightseed, Inc. Method for modulating metabolism
WO2019183587A1 (en) 2018-03-23 2019-09-26 Yumanity Therapeutics, Inc. Compounds and uses thereof
KR20220007845A (ko) 2019-01-24 2022-01-19 유마니티 테라퓨틱스, 인크. 화합물 및 이의 용도
AU2020383340A1 (en) 2019-11-11 2022-06-09 Brightseed, Inc Extract, consumable product and method for enriching bioactive metabolite in an extract
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
KR102408566B1 (ko) * 2020-04-09 2022-06-16 대한민국 터미날리아 비아라타 추출물을 이용한 피부 주름 개선용 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005053864A (ja) * 2003-08-06 2005-03-03 Ryukyu Bio Resource Kaihatsu:Kk 糖尿病疾患予防・治療剤
JP2006188486A (ja) * 2004-12-07 2006-07-20 Toyo Shinyaku:Kk 体脂肪蓄積抑制または低減剤
JP2008537539A (ja) * 2005-02-23 2008-09-18 アヴェスタジェン リミテッド 植物抽出物およびそのための方法と使用

Also Published As

Publication number Publication date
NZ701133A (en) 2016-08-26
EP2841080A4 (en) 2015-11-25
TW201343174A (zh) 2013-11-01
EP2841080A1 (en) 2015-03-04
US20150290265A1 (en) 2015-10-15
MX2014012742A (es) 2015-04-08
BR112014026326A2 (pt) 2017-06-27
JP2015514797A (ja) 2015-05-21
CN104244962A (zh) 2014-12-24
IN2014MN02269A (enEXAMPLES) 2015-07-24
WO2013160811A1 (en) 2013-10-31
RU2014145931A (ru) 2016-06-20
SA113340494B1 (ar) 2015-12-24
IL235317A0 (en) 2014-12-31
KR20150003862A (ko) 2015-01-09
AU2013254329A1 (en) 2014-11-13

Similar Documents

Publication Publication Date Title
CA2870907A1 (en) Composition for treating metabolic disorders
Mitra et al. Antidiabetic and hypolipidemic effects of mahanimbine (carbazole alkaloid) from Murraya koenigii (rutaceae) leaves
Noumedem et al. Lactuca sativa
US20180099020A1 (en) Extract from indigo naturalis and a process for preparing the same
AU2013320237B2 (en) Novel extracts of Cynara scolymus, Coffea spp. and Olea europaea for the treatment of metabolic syndrome
Kumar et al. Phytochemical investication and heptoprotective evalution acacia rubica extract isonized and paracetamol indused animal toxicity
CN101918080A (zh) 欧洲白蜡树种子提取物及其治疗应用
EP3595691A1 (en) Herbal composition
Vikhe et al. Antidiabetic and antihyperlipidemic effects of crude fractions and isolated compound from Striga orobanchioides Benth on streptozotocin induced diabetic rats
CA2866260A1 (en) Herbal composition for the treatment of metabolic disorders
Khalil et al. Nano-encapsulated form of citrus medica for osteoporosis treatment in animal model
JP4863875B2 (ja) ウチワサボテン植物の部分および／またはそれからの抽出物を含むうつ病治療剤
Arun et al. Comapartive study on hepatoprotective activity of Phyllanthus amarus and Eclipta prostrata against alcohol induced in albino rats
JP6758799B2 (ja) 医薬組成物
Irchhaiya et al. Plant profile, phytochemistry and pharmacology of Bauhinia variegata Linn.(Kachnar): an overview
JP2010522740A (ja) α１アドレナリン受容体の阻害のための水溶性Ｏｐｕｎｔｉａ抽出物
Tharaheswari et al. Fenugreek seed extract stabilize plasma lipid levels in type 2 diabetes by modulating PPARs and GLUT4 in insulin target tissues
Asir et al. Antidiabetic activity of aqueous and ethanolic extracts of Passiflorafoetida L. in alloxan induced diabetes rats
Alex et al. In vitro hepatoprotective activity of extracts of Viburnum punctatum Buchham Ex D. Don against carbon tetrachloride induced toxicity
Mani et al. Pharmacological review of achyranthes aspera linn.
Kushwaha et al. Hepatoprotective activity of ethanolic extract of Euphorbia royleana linn in carbon tetrachloride treated guinea pig
Ugwu et al. Preliminary Standardization of Fadogia cienkowskii Schweinf (Rubiaceae) Leaves and Evaluation of the Anti-inflammatory Activity of the Methanol Extract.
Balkrishna et al. Looking beyond the Roots: Exploring the Untapped Potential of Withania somnifera
Suloev et al. Isolation of individual flavonoids from Solidago canadensis L
CN101015545B (zh) 苯丙酸苯丙酯类化合物在制备抗氧化保肝及保护脑损伤药物中的用途

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20190423